<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273767</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC 05 04</org_study_id>
    <nct_id>NCT00273767</nct_id>
  </id_info>
  <brief_title>Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB</brief_title>
  <acronym>EPOetCEC</acronym>
  <official_title>Double-blind Phase II Pilot Monocentric Randomized Clinical Trial Evaluating the Effect of a Preliminary Administration of Erythropoietin on Different Markers of Cardiac Ischemia Induced by Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to observe the effects of erythropoietin administration on different
      blood markers of ischaemic cardiac lesions induced by cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A new property of erythropoietin (EPO), independent of its hematopoietic role, has recently
      been discovered. Indeed, it has been reported that this hormone, following binding to its
      cardiac or cerebral receptors, is able to induce a spectacular cellular protection against
      ischemic injury. These cardioprotective and neuroprotective effects have been observed
      experimentally in rodents as well as clinically in humans. In particular, our team has
      demonstrated that the administration of NeoRecormon® protects the heart against ischemia in
      the rat by significantly improving its recovery.

      In view of these exciting experimental results and of the growing interest of the scientific
      community for cytoprotective effects of EPO, we are planning the first clinical study
      examining the cardiac and cerebral protective effects of EPO (NeoRecormon®) in the setting of
      cardiac surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve and maximal plasmatic level of troponin-T, NT-pro-BNP, and creatine kinase-MB (CK-MB) after cardiopulmonary bypass</measure>
    <time_frame>at anaesthesia (ti), at the end of the cardiopulmonary bypass (t0), puis 6 h, 12 h, 24 h et 48h after the end of the cardiopulmonary bypass</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve and maximal plasmatic level of protein S-100 after cardiopulmonary bypass</measure>
    <time_frame>at anaesthesia (ti), at the end of the cardiopulmonary bypass (t0), puis 6 h, 12 h, 24 h et 48h after the end of the cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood level of erythropoietin</measure>
    <time_frame>at injection and 6 hours after the end of cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epoetin beta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo of NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin beta</intervention_name>
    <description>800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>60ml of NaCl IV slow</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary bypass surgery.

          -  Surgery not urgent.

          -  Left ventricular ejection fraction (LVEF) &gt; 40.

          -  Informed consent form signed.

        Exclusion Criteria:

          -  Valvular surgery.

          -  Surgery with beating heart, with or without cardiopulmonary bypass.

          -  Carotid bypass surgery.

          -  Myocardial infarction less than 30 days.

          -  Previous history of cardiac surgery.

          -  Kidney failure (creatinine &gt; 200 µmol/l).

          -  Uncontrolled hypertension.

          -  Unstable angina.

          -  Risk of deep venous thrombosis.

          -  Vascular cerebral attack less than 30 days.

          -  Malignant tumour.

          -  Phenylketonuria.

          -  Allergy to erythropoietin.

          -  Previous programmed blood donation.

          -  Pregnancy and feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier CHAVANON, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiac Surgery Department - CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res. 2004 Aug 1;63(2):208-16. Review.</citation>
    <PMID>15249178</PMID>
  </reference>
  <reference>
    <citation>Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002 Aug;8(8):495-505.</citation>
    <PMID>12435860</PMID>
  </reference>
  <reference>
    <citation>Johnsson P, Bäckström M, Bergh C, Jönsson H, Lührs C, Alling C. Increased S100B in blood after cardiac surgery is a powerful predictor of late mortality. Ann Thorac Surg. 2003 Jan;75(1):162-8.</citation>
    <PMID>12537211</PMID>
  </reference>
  <reference>
    <citation>Joyeux-Faure M, Godin-Ribuot D, Ribuot C. Erythropoietin and myocardial protection: what's new? Fundam Clin Pharmacol. 2005 Aug;19(4):439-46. Review.</citation>
    <PMID>16011730</PMID>
  </reference>
  <reference>
    <citation>Kerbaul F, Giorgi R, Oddoze C, Collart F, Guidon C, Lejeune PJ, Villacorta J, Gouin F. High concentrations of N-BNP are related to non-infectious severe SIRS associated with cardiovascular dysfunction occurring after off-pump coronary artery surgery. Br J Anaesth. 2004 Nov;93(5):639-44. Epub 2004 Sep 3.</citation>
    <PMID>15347604</PMID>
  </reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2006</study_first_submitted>
  <study_first_submitted_qc>January 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Frédérick Marie</name_title>
    <organization>University Hospital Grenoble</organization>
  </responsible_party>
  <keyword>troponin T</keyword>
  <keyword>CK-MB</keyword>
  <keyword>protein S-100</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

